This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): Serlect
Description: Serdolect is an atypical antipsychotic with a higher affinity for the serotonin 5-HT2 receptor relative to its affinity for the dopamine D-2 receptor. Though the exact mechanism is unclear (either due to a difference in affinities for such receptors or fast dissociation from the D-2 receptor), atypical antipsychotics are able to produce an antipsychotic effect (through blockade of D-2 receptors in the ventral striatum) with fewer extrapyramidal motor function side effects (or EPSs, which are caused by blockade of D-2 receptors in the dorsal striatum).
Sertindole has high affinity for dopamine D2, alpha-1-adrenoceptors and serotonin 5-HT2A and 5-HT2c receptors, where has antagonistic properties (an inverse agonist at the latter).).
Key receptor interactions include:
D2: 7 nM;
5HT2A: 0.3 nM;
5HT1A: 280 nM;
5HT2C: 0.7 nM;
alpha-1 adrenergic: 4 nM;
alpha-2 adrenergic: 640 nM;
H1: 130 nM;
M1: >5000 nM;
Deal Structure: In August 1991, Abbott Laboratories and H. Lundbeck A/S signed a licensing agreement giving Abbott the rights to develop and market in the United States, sertindole, which was discovered by H. Lundbeck A/S.
After Abbott withdrew the U.S. application for the drug in 1998, Lundbeck now holds the global rights to Serdolect.
Additional information available to subscribers only: